Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WinGlio: Neoadjuvant Ipilimumab in Newly Diagnosed Glioblastoma
NCT07134842Phase 1Recruiting
- Sponsor
- University College London
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab in glioblastoma (GBM), sponsored by University College London. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 3 months, Overall Survival at 12 months and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07134842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134842.